Trends in the Incidence and Outcomes of Disseminated Intravascular Coagulation in Critically Ill Patients (2004-2010)

Singh, Balwinder; Hanson, Andrew C.; Alhurani, Rabe E.; Wang, Shihan; Herasevich, Vitaly; Cartin‐Ceba, Rodrigo; Kor, Daryl J.; Gangat, Naseema; Li, Guangxi

doi:10.1378/chest.12-2112

Cited by 45 publications

(43 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, we could not determine the effect of rTM itself because this study did not include a control group in which rTM was not administered, since rTM is the first-line drug for the treatment of DIC in our hospital. At least, the mortality rate in this study was 44%, which is equivalent to or better than those reported in earlier studies [1]. In addition, this study suggested that administration of rTM after progression of disease causing DIC might be less effective.…”

Section: Discussionsupporting

confidence: 66%

“…Third, group S had more number of female patients. Sepsis-related mortality rates are reported to be higher in female patients than in male patients [1]. Although gender was highly associated with the outcomes in our multivariate logistic regression analysis, the late administration of rTM was also a risk factor for mortality.…”

Section: Discussionmentioning

confidence: 61%

“…Disseminated intravascular coagulation (DIC) occurs in 9%-19% of patients in the intensive care unit (ICU), and rate of mortality associated with DIC is as high as 45%-78% [1]. The development of new therapies to treat DIC is expected because this rate has not changed in the last 10 years [1].…”

Section: Introductionmentioning

confidence: 99%

“…The development of new therapies to treat DIC is expected because this rate has not changed in the last 10 years [1]. In Japan, recombinant human soluble thrombomodulin-alpha (rTM) (Recomodulin, Asahi Kasei Pharma, Tokyo, Japan) has been available as a therapeutic DIC drug since 2008.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Administration of recombinant thrombomodulin before progression of disease causing disseminated intravascular coagulation might be better compared with administration after progression of disease

et al. 2014

View full text Add to dashboard Cite

Background: As disseminated intravascular coagulation (DIC) causes multiple organ failure, recombinant thrombomodulin (rTM) is widely used in Japan for treating DIC. However, the optimal timing of rTM administration has not yet been determined. We hypothesized that the administration of rTM before progression of disease causing DIC might be better for the treatment of DIC than that after progression of disease.

show abstract

Section: Discussionsupporting

confidence: 66%

Section: Discussionmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Administration of recombinant thrombomodulin before progression of disease causing disseminated intravascular coagulation might be better compared with administration after progression of disease

et al. 2014

View full text Add to dashboard Cite

show abstract

“…22 Furthermore, findings from the Olmsted County population have shown to be generalizable to the Upper Midwest population and provide invaluable information regarding various diseases, which are consistent with the national data. 23,24 …”

Section: Discussionmentioning

confidence: 99%

Interrater Variability in Identifying Ventilator Associated Pneumonia Using Six Different Definitions

Nusair¹,

Singh²,

Ding³

et al. 2015

MJM

Self Cite

View full text Add to dashboard Cite

Bone Marrow‐Derived Mesenchymal Stem Cells‐Mediated Protection Against Organ Dysfunction in Disseminated Intravascular Coagulation Is Associated With Peripheral Immune Responses

Wang

et al. 2017

J of Cellular Biochemistry

View full text Add to dashboard Cite

Disseminated intravascular coagulation (DIC) is a fatal thrombohemorrhagic disorder. Bone marrow-derived mesenchymal stem cells (BMSCs) are multipotent stem cells that have tremendous therapeutic effect. Our aim was to explore whether the immune mechanisms were associated with BMSCs-afforded protection against DIC. We generated a rat model of DIC by lipopolysaccharide (LPS, 3 mg/kg) injection via the tail vein. In the treatment group, rats were pre-treated with 1 × l0 , 1 × l0 , 1 × l0 , and 1 × l0 allogeneic BMSCs before LPS injection. Blood sample was withdrawn from the abdominal aorta at 0 (before), 4, and 8 h after LPS injection and used for biochemical analyses. After experiments, the mice were sacrificed and their organs were harvested and observed by H&E and PTAH staining. Continuous infusion of LPS into the rats gradually impaired the hemostatic parameters and damaged organ functions. However, pre-treatment with BMSCs dose-dependently improved the hemostatic parameters. Meanwhile, the treatment significantly suppressed the fibrin microthrombi formation and alleviated liver, heart, lung, and renal injuries. Flow cytometry analysis demonstrated that BMSCs pre-treatment inhibited LPS-induced upregulation of CD3 CD8 T cells and CD3 /CD161a NKT cells in the peripheral blood. BMSCs pre-treatment reversed the upregualtion of the B-cell population and the percentage of CD43 /CD172a monocytes in the DIC models. Finally, BMSCs pre-treatment decreased the levels of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), and interleukin-6 (IL-6) and increased the levels of interleukin-10 (IL-10) in LPS-induced DIC models. Pre-treatment with BMSCs can reduce coagulation and alleviate organ dysfunction via peripheral immune responses in LPS-induced DIC rat model. J. Cell. Biochem. 118: 3184-3192, 2017. © 2017 Wiley Periodicals, Inc.

show abstract

Trends in the Incidence and Outcomes of Disseminated Intravascular Coagulation in Critically Ill Patients (2004-2010)

Cited by 45 publications

References 36 publications

Administration of recombinant thrombomodulin before progression of disease causing disseminated intravascular coagulation might be better compared with administration after progression of disease

Administration of recombinant thrombomodulin before progression of disease causing disseminated intravascular coagulation might be better compared with administration after progression of disease

Interrater Variability in Identifying Ventilator Associated Pneumonia Using Six Different Definitions

Bone Marrow‐Derived Mesenchymal Stem Cells‐Mediated Protection Against Organ Dysfunction in Disseminated Intravascular Coagulation Is Associated With Peripheral Immune Responses

Contact Info

Product

Resources

About